µ¼Ó²¡Àí»úÖÆ¡¢ÐÂÒ©Ñз¢¡¢ÕïÁƹÜÀíÈ«·½Î»ÁýÕÖ £¬Ò»ÆðÀ´¿´°¢¶û´Äº£Ä¬²¡ÁìÓò×îнøÕ¹£¡
2023Äê11ÔÂ18ÈÕ £¬ÓÉÖйúÄÔ½¡¿µÐж¯×¨¼ÒίԱ»áÖ¸µ¼ £¬¾«×¼Ò½Ñ§Ñо¿Ó빤ҵÉú³¤ÁªÃ˼°ÉϺ£Ò½Ñ§´´ÐÂÉú³¤»ù½ð»áÖ÷°ì¡¢À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¶¦Á¦Ö§³ÖµÄ2023Äê°¢¶û´Äº£Ä¬²¡á¯ÁëÂÛ̳ÓÚ±±¾©Ê¢´óÕÙ¿ª £¬¹úÄÚÍâ¶àλÈÏÖªÕÏ°ÁìÓòµÄר¼ÒѧÕßÆë¾ÛÒ»Ìà £¬Î§ÈÆÄÔ½¡¿µ¡¢°¢¶û´Äº£Ä¬²¡£¨AD£©²¡Àí»úÖƼ°ÉúÎï±êÖ¾Îï¡¢¼²²¡ÐÞÊÎÖÎÁÆ£¨DMT£©Ò©Îï×îÐÂÑо¿Êý¾Ý¡¢»¼Õß¹ÜÀíµÈÈȵ㻰ÌâÕ¹¿ªÁËÉîÈë̽ÌÖ £¬¿ªÆôADÁìÓò¿çʱ´úÉú³¤µÄиñʽ¡£
ÔÚ¿ª³¡Ö´ǻ·½Ú £¬´ó»áÖ÷ϯÉϺ£Ò½Ñ§´´ÐÂÉú³¤»ù½ð»áÖ´ÐÐÀíʳ¤Íõ²¨Å®Ê¿¡¢Ê׶¼Ò½¿Æ´óѧÐûÎäÒ½Ôº¼Ö½¨Æ½½ÌÊÚ¡¢¸£½¨Ò½¿Æ´óѧÁ¥ÊôкÍÒ½Ôº³ÂÏþ´º½ÌÊÚÖ¿ª³¡´Ç £¬¾ùÌåÏÖµ±Ç°ADÁìÓòÒÑÓÀ´ÁËÀúÊ·ÐԵķÉÔ¾ÓëÍ»ÆÆ¡£
ͼ ÉϺ£Ò½Ñ§´´ÐÂÉú³¤»ù½ð»áÖ´ÐÐÀíʳ¤Íõ²¨Å®Ê¿
ͼ Ê׶¼Ò½¿Æ´óѧÐûÎäÒ½Ôº¼Ö½¨Æ½½ÌÊÚ
ͼ ¸£½¨Ò½¿Æ´óѧÁ¥ÊôкÍÒ½Ôº³ÂÏþ´º½ÌÊÚ
»áÒéÒÁʼ £¬Ê׶¼Ò½¿Æ´óѧÁ¥Êô±±¾©Ìì̳ҽԺÍõÓµ¾ü½ÌÊÚÊ×ÏÈΪÎÒÃǽéÉÜÁËÄÔ½¡¿µ¹ÜÀíÖÐÐĵĿ´·¨¡¢ÏÖ×´ÓëÕ¹Íû¡£ÄÔ½¡¿µÊÇʵÏÖ¿ÉÁ¬ÐøÉú³¤Ä¿±êµÄºËÐÄ £¬²¢Ã÷È·Ìá³öÁËÄÔ½¡¿µ½ç˵µÄËÄÏîÄÚÈÝ £¬¼´ÄԽṹÕý³£¡¢ÄÔ¹¦Ð§Õý³£¡¢Éç»áÊÊÓ¦Á¼ºÃ¡¢ÎÞÉñ¾¾«Éñ¼²²¡ £¬²¢Ö¸³öÄÔ½¡¿µ¹ÜÀíÖÐÐÄÓ¦ÒÔÕâËĸöά¶ÈΪºËÐÄÃ÷È·Ö°Äܶ¨Î» £¬ÒÔ¸üºÃµØÍƶ¯ÎÒ¹úÄÔ½¡¿µÉú³¤¡£
ͼ ÍõÓµ¾ü½ÌÊÚ
Í»ÆƱÚÀÝ¡¢¿ªÆôδÀ´ £¬ADÕïÁÆ¿ªÆôÐÂƪÕÂ
Ëæ×ÅADÖ²¡»úÖƵÄÃ÷ÎúÓëDMTÒ©ÎïµÄÉú³¤ £¬½üÄêÀ´ADÉúÎï±êÖ¾ÎïµÄÑо¿Èç»ðÈçݱ¡£ÖÐÄÏ´óѧÏæÑÅÒ½ÔºÉòè´½ÌÊÚ·ÖÏíÁËADÉúÎï±êÖ¾ÎïµÄ×îÐÂÑо¿½øÕ¹¡£ÔÚ½ñÄêµÄ°¢¶û´Äº£Ä¬²¡Ð»á¹ú¼Ê»áÒ飨AAIC£©´ó»áÉÏÐû²¼ÁËAD×îÐÂÕï¶Ï³ß¶È £¬½¨Òéͨ¹ýºËÐÄÉúÎï±êÖ¾ÎｫAD½øÐзÖÆÚ¼°Õï¶ÏAD £¬ÓÉ´ËÔÚADµÄÁÙ´²·ÖÆÚÖÐÔö¼ÓÁË0½×¶Î£¨stage 0£©£»´ËÍ⻹½éÉÜÁ˶àÖÖѪҺÉúÎï±êÖ¾ÎïµÄÑо¿½øÕ¹¼°ÆäÔÚÕïÁÆÖеÄÓ¦ÓüÛÖµ £¬²¢¶ÔA¦ÂºÍTau-PETÔÚADÕï¶ÏÖеĺÏÀíÓ¦Óøø³öÖî¶à½¨Òé¡£
ͼ Éòè´½ÌÊÚ
Ê׶¼Ò½¿Æ´óѧÐûÎäҽԺκ´ä°Ø½ÌÊÚ½â¶ÁÁË×îÐÂDMTÒ©ÎïÏà½ÏÓÚ´«Í³Ò©ÎïµÄÐÂÄ¿±êºÍÐÂÒªÇó £¬ÈçÇå³ý²¡Àí²úÎïºÍÑÓ»º¼²²¡½ø³Ì £¬¶øÂØ¿¨Ä¹µÄÑо¿Êý¾Ý¶¼ºÜºÃµÄÖ§³ÖÁËDMTµÄÖÎÁÆ»ñÒæ¡£ÂØ¿¨Ä¹¾ßÓÐÃ÷È·µÄÁÆЧºÍÁ¼ºÃµÄÄþ¾²ÐÔºÍÄÍÊÜÐÔ £¬´ú±í¿¹A¦Âµ¥¿¹Ò©ÎïÍ»ÆÆÖØΧ¡¢¿ªÆôDMTʱ´úµÄÐÂƪÕ¡£
ͼ κ´ä°Ø½ÌÊÚ
κ´ä°Ø½ÌÊÚ½éÉܵÀ £¬ÂØ¿¨Ä¹Á¬ÐøÖÎÁƿɼõ»ºÈÏÖªºÍ¹¦Ð§µÄË¥Í˺͸üºÃά³Ö¹¦Ð§ £¬ÕÕÁϸºµ£¸üÉÙ £¬ÓÈÆäÔÚµÍTauˮƽÑÇ×飨¼´¸üÔçÆÚµÄAD»¼Õߣ©ÖпÉÑÓ»ºÁÙ´²³Õ´ôÆÀ·Ö×ܺÍÁ¿±í£¨CDR-SB£©Ë¥ÍË549% £¬ÌáʾԽÔçÖÎÁÆ £¬»¼Õß»ñÒæÔ½¶à¡£²»½öÈç´Ë £¬ÔçÆÚÆô¶¯ÂØ¿¨Ä¹ÖÎÁÆ £¬»¹¿ÉÈÃ76%µÄ¸üÔçÆÚAD»¼Õß»ñµÃÈÏÖªºÍ¹¦Ð§Î¬³Ö £¬60%»¼ÕßµÄÈÏÖªºÍ¹¦Ð§µÃµ½¸ÄÉÆ[2]¡£
ͼ ÔçÆÚÆô¶¯ÂØ¿¨Ä¹ÖÎÁÆÈÏÖªºÍ¹¦Ð§Î¬³Ö¡¢¸ÄÉÆ
ÔÚADÕï¶Ï¼°ÖÎÁÆÁìÓò¶¼È¡µÃÍ»ÆƵĵ±Ï £¬ADÁÙ´²ÕïÁÆʵ¼ùÒ²ÌáÉÏÁËÒéÊÂÈճ̡£¸çÂ×±ÈÑÇ´óѧLawrence Honig½ÌÊÚΪÎÒÃǽøÐÐÁËÖ÷ÌâΪ¡°Healthcare System Readiness for New Treatments for Alzheimer Disease¡±µÄÊÚ¿Î £¬Lawrence½ÌÊÚÖ¸³ö £¬ADÔ´ÐÔMCl¼°Çá¶ÈADµÈÔçÆÚAD»¼Õß¡¢ÄÔ¼¹Òº»òPET£¨ÉõÖÁѪ½¬£©¼ì²é½á¹ûÈ·ÈÏÓеí·ÛÑùÂѰ׵Ļ¼ÕßÈËȺӦ¾¡Ôç½ÓÊÜDMTÖÎÁÆ¡£
ͼ Lawrence Honig½ÌÊÚ
ÔÚÉÏÎç»áÒéµÄ×îºó £¬½â·Å¾ü×ÜÒ½Ôº½âºã¸ï½ÌÊÚÖ÷³ÖÁËÌÖÂÛ»·½Ú £¬Õã½´óѧҽѧԺÁ¥ÊôµÚÒ»Ò½ÔºÂÞ±¾Ñà½ÌÊÚ¡¢ÇൺÊÐÊÐÁ¢Ò½ÔºÌ·À¼½ÌÊÚÓëLawrence Honig½ÌÊھ͵±Ç°µÄDMTÒ©ÎïÊÇ·ñÄܹ»ÕæÕýΪAD»¼Õß´øÀ´»ñÒæ¡¢DMTÒ©ÎïÈçºÎ²ÅÆøÔÚÁÙ´²Êµ¼ùÖз¢»Ó×î´ó¼ÛÖµÒÔ¼°ÄÔ½¡¿µÖÐÐĵĽ¨ÉèÕ¹¿ªÁ˾«²ÊÌÖÂÛ¡£
ͼ ´ó¿§É³·¢Ðã
×·¸ùËÝÔ´ £¬Ã÷È·²¡Àí»úÖÆ £¬Íƶ¯ADÕïÁÆÉú³¤
µ±ÌìÏÂÎç»áÒ鿪ʼʱ £¬´ó»áÖ÷ϯ±±¾©´óѧµÚÁùÒ½ÔºÓÚÐÀ½ÌÊÚ¡¢É½¶«µÚÒ»Ò½¿Æ´óѧÁ¥ÊôÊ¡Á¢Ò½Ôº¶Åâù·å½ÌÊÚÖ´ǵÀ £¬ÄîÄî²»Íü £¬±ØÓлØÏì £¬¾¹ý¶þÊ®¶àÄêÀ´µÄ²»Ð¸Å¬Á¦ £¬ADÕïÁÆÁìÓòÖÕÓÚÏÆ¿ªÁËÈ«ÐÂƪÕ¡£
ͼ ÓÚÐÀ½ÌÊÚ
ͼ ¶Åâù·å½ÌÊÚ
ÉϺ£½»Í¨´óѧÁ¥ÊôµÚÁùÈËÃñÒ½Ôº¹ùÆðºÆ½ÌÊÚ½éÉÜÁ˽üÆÚAD×îеIJ¡Àí»úÖÆ·¢ÏÖ¡£¶àÖÖADÖ²¡»úÀíµÄ¼Ù˵ÓÐÁËеÄÀ©³äºÍ·¢ÏÖ £¬¼´A¦Â¹Ñ¾ÛÌå¿É×÷Ϊ¡°ÖÖ×Ó¡±¼ÓËÙA¦Â³Á»ý £¬Í¬Ê±¿ÉÓëTauÂÑ°×е÷×÷ÓÃ[4,5]¡£ÂØ¿¨Ä¹Í¨¹ýÓÕµ¼Ð¡½ºÖÊϸ°ûÇå³ý×î¾ß¶¾ÐÔµÄA¦Â¹Ñ¾ÛÌåºÍÔÏËά £¬²¢Ô¤·À°ß¿éÉú³É £¬Í¬Ê±¼õÉÙÏÂÓÎTau²¡Àí½øÕ¹ £¬ÒÔ´ËÓÐЧÑÓ»ºAD½øÕ¹ £¬ÑéÖ¤ÁËÒÔ¡°A¦Â¼¶ÁªÑ§Ëµ¡±ÎªÀíÂÛ»ù´¡µÄÖÎÁƼÆı[6,7]¡£
ͼ ¹ùÆðºÆ½ÌÊÚ
ËÄ´¨´óѧ»ªÎ÷Ò½Ôº³ÂÇÛ½ÌÊÚÖ¸³ö £¬A¦ÂÔÚÌåÄÚÒÔ¶àÖÖÐÎʽ´æÔÚ £¬µ±A¦Â¾Û¼¯³Á»ý´óÓÚÇå³ýʱ»áÔì³É³Á»ý¹ýÔØ £¬´Ó¶øÓÕ·¢AD[8]¡£A¦ÂÒì³£¾Û¼¯ºÍÍ»´¥¹¦Ð§Ê§µ÷·¢ÉúÔÚTau²¡ÀíÁ÷´«¡¢´óÄԽṹ¸Ä±ä£¨Éñ¾Ôª¶ªÊ§£©¡¢·ºÆðÁÙ´²ÌåÏÖ»òÖ¢×´µÈ½×¶Î֮ǰ £¬Æä³Á»ýÓëADµÄ½øÕ¹·çÏÕ¾ßÓÐÏà¹ØÐÔ £¬Òò´ËA¦Â³ÉΪĿǰADÒ©ÎïÑз¢¹ÜÏßÖеÄÈȵã×÷ÓðÐλ[9]¡£
ͼ ³ÂÇÛ½ÌÊÚ
ÄÏ¿ª´óѧÁ¥ÊôÌì½òÊл·ºþÒ½Ôº¼ÍÓ½ÌÊÚÒÔ¡°AD£º´ÓÁÙ´²µ½²¡ÀíÕï¶Ï¡±·ÖÏíÁËÈçºÎ¾«×¼ÔçÆÚAD»¼Õß £¬²¡Àí½á¹ûÊÇÕï¶ÏADµÄ½ð³ß¶È £¬µ«ÈçºÎÒÔ¸üСµÄ´´ÉËʵÏÖAD»¼ÕßµÄÔçÆÚÕï¶Ï£¿ÔÚ±¾´Î³ÂËßÖÐ £¬¼ÍÓ½ÌÊÚÖ¸³öÁ˽ṹӰÏñѧ¡¢·Ö×ÓÓ°Ïñѧ¡¢ÑªÒº±êÖ¾ÎïÔÚADÕï¶ÏÖеIJîÒì×÷Óá£
ͼ ¼ÍÓ½ÌÊÚ
½ÓÏÂÀ´½â·Å¾ü×ÜÒ½Ôº¼Ö½¨¾ü½ÌÊÚÏêϸÂÛÊöÁË¡°A¦Â·Ö×ÓÓ°Ïñ¼¼Êõ¡±ÔÚÖйúµÄÓ¦ÓÃÏÖ×´ £¬Ìá³öA¦Â-PETÓ°ÏñѧÊÊÓÃÓÚÁ¬Ðø»ò½øÕ¹ÐԵIJ»ÐнâÊ͵ÄMCI»¼Õß¡¢¿ÉÄÜΪADµ«ÁÙ´²Ö¢×´»ò²¡³Ì½øÕ¹²»µäÐ͵Ļ¼Õß¡¢½øÕ¹ÐÔ³Õ´ô»¼Õ߶øÇÒ·¢²¡ÄêÁäÔ磨< 65Ë꣩ £¬ÎÒ¹úµÄÓ°Ïñѧ¹¤ÒµÓ¦¾¡¿ì¸ú½øѧÊõÑо¿µÄ½Å²½×ßÔÚ¹ú¼ÊµÄÇ°ÑØ¡£
ͼ ¼Ö½¨¾ü½ÌÊÚ
ÉîÛÚÍåʵÑéÊÒ¹ùÌڷɲ©Ê¿¼°¹ãÖÝÒ½¿Æ´óѧÁ¥ÊôÄÔ¿ÆÒ½ÔºÖÓЦ÷½ÌÊÚ·Ö±ðÕë¶ÔADÌåÒºÉúÎï±êÖ¾ÎïµÄ³£Óüì²âÒªÁì £¬¼´µ¥·Ö×Ó¼¼ÊõºÍ»¯Ñ§·¢¹â/µç»¯Ñ§·¢¹â¼¼ÊõµÄÓ¦ÓýøÐÐÁË·ÖÏí £¬Ö¸³öѪ½¬ÉúÎï±êÖ¾Îï¼ì²â¾ßÓÐ΢´´ÐԺͱãÀûÐÔ £¬±ãÓÚÁÙ´²Ê¹Óà £¬ÔÚADÔçÆÚÕï¶ÏÖоßÓо޴óÓ¦ÓÃDZÁ¦ £¬Èçp-Tau217ÊÇADÕï¶Ï·Ç³£ÓÐÇ°¾°µÄÉúÎï±êÖ¾Îï £¬Äܹ»¾¡Ôç¼ì²âµ½ADµÄ²¡Àí±ä»¯[10]¡£
ͼ ¹ùÌڷɲ©Ê¿
ͼ ÖÓЦ÷½ÌÊÚ
ÌåÒºÉúÎï±êÖ¾ÎïºÍÓ°ÏñѧÉúÎï±êÖ¾Îï¿ÉÓ¦ÓÃÓÚADµÄÔçÆÚÕï¶Ï¡¢¾«×¼Ñ¡Ôñ¿É´ÓDMTÒ©ÎïÖлñÒæµÄAD»¼ÕßÒÔ¼°¼à²âÖÎÁÆ·´Ó³µÈÒªº¦¹ý³Ì £¬µ±Ç°²»½öÉúÎï±êÖ¾ÎïµÄÖÖÀ༰ЧÄÜÕýÔÚÔö¼Ó £¬Æä¼ì²âÒªÁìÒ²ÓÐÁ˸üС£ÔÚ½áÊøÕâÒ»»·½ÚµÄ½²¿Îºó £¬ÔÚ¶Åâù·å½ÌÊÚµÄÖ÷³ÖÏ £¬ÖØÇìÒ½¿Æ´óѧÁ¥ÊôµÚÒ»Ò½ÔºÂÀÑó½ÌÊÚ¡¢±±¾©ÐºÍҽԺ볿êͽÌÊÚ¡¢¼ªÁÖ´óѧµÚÒ»Ò½ÔºËïÀò½ÌÊÚ¡¢½â·Å¾ü×ÜÒ½ÔºÕŽõÃ÷½ÌÊÚ¾ÍÖÚ¶àÉúÎï±êÖ¾ÎïµÄÁÙ´²Êµ¼ùÓ¦ÓÃÕ¹¿ªÁËÉîÈëÌÖÂÛ¡£
AD¿É·À¿É¿Ø £¬È«³Ì»ý¼«Ó¦¶Ô¿É¼õÇá¼²²¡¸ºµ£
¡°È«Çò³Õ´ô»¼ÕßµÄÕÕ»¤ÏÖ×´¿°ÓÇ £¬ÇÒÕÕ»¤ÕßÃæÁÙµÄѹÁ¦Ò²²»ÈݺöÊÓ¡£¡±ÉϺ£Êо«ÉñÎÀÉúÖÐÐÄÀîϼ½ÌÊÚÔÚÊÚ¿ÎÖÐÖ¸³ö¡£Àîϼ½ÌÊÚ·ÖÏíÁËSMARRTÑо¿ºÍFINGERÑо¿µÄ×îнá¹û £¬Í¨¹ýϵͳÐÔ¡¢¶àÁìÓòµÄ¸öÐÔ»¯¸ÉÔ¤¿ÉÏÔÖø¸ÄÉÆÊÜÊÔÕßÈÏÖª²¢Ìá¸ßÉú»îÖÊÁ¿ £¬½µµÍAD·çÏÕ £¬ÇÒÆä¸ÉÔ¤½á¹ûËƺõ²»ÊÜÒÅ´«ÒòËصÄÓ°Ï죻ǿÁÒ½¨ÒéÔÚÕû¸öÉúÃü¹ý³ÌÖÐ £¬¶ÔÉú»î·½Ê½¡¢ºÏ²¢Ö¢µÈÖصãÒòËØʵʩ¸ÉÔ¤[11]¡£
ͼ Àîϼ½ÌÊÚ
Õë¶Ô»¼Õß¹ÜÀíÕâÒ»ÖØÒªÒéÌâ £¬Õã½´óѧҽѧԺÁ¥ÊôÉÛÒÝ·òÒ½Ôº³Â쿽ÌÊÚ¡¢ÄϾ©Ò½¿Æ´óѧÁ¥ÊôÄÔ¿ÆҽԺʯ¾²Æ¼½ÌÊÚ¡¢ÉϺ£½»Í¨´óѧҽѧԺÁ¥ÊôÈð½ðÒ½ÔºÌÀÜö¶¬½ÌÊÚ¡¢¶«ÄÏ´óѧÁ¥ÊôÖдóҽԺл´ºÃ÷½ÌÊÚ¡¢¹ã¶«Ê¡ÈËÃñÒ½ÔºÕÔ½àð©½ÌÊÚ¾ÍÔçÆÚAD»¼ÕßµÄÈ«³Ì¹ÜÀí £¬ÒÔ¼°ÔÚÁÙ´²ÉϽÓÊÜDMTÒ©ÎïÖÎÁƵÄAD»¼ÕߵĹ淶¹ÜÀí½øÐÐÁËÌÖÂÛ¡£ÔÚÓÃÒ©Ç°½øÐÐÈ«ÃæÆÀ¹À¡¢Ñϸñɸ²é»¼ÕßÊÇAD¾«×¼ÓÃÒ©µÄ»ùʯ £¬¿É¶Ô»¼Õß¿ªÕ¹¸ü¾ßÕë¶ÔÐÔµÄÖÎÁÆ £¬ÓÃÒ©ºó½èÖúÊý×Ö»¯¹¤¾ß¿É×ÊÖúÁÙ´²Ò½Éú¼à²â»¼Õß²»Á¼·´Ó³¡¢ÆÀ¹ÀÖÎÁÆЧ¹û¡£
С½á
±¾´Î´ó»áµÄÄÚÈÝÅöײÔÚADµÄ¶àÁìÓòÖдεڿª»¨ £¬Õï¶ÏÁìÓòÓжàÏîÉúÎï±êÖ¾ÎïÑо¿µÄ½øÕ¹ £¬ÖÎÁÆÁìÓòÓÐÂØ¿¨Ä¹µÈÐÂÒ©ÖØ°õÉÏÊÐ £¬²¡Àí»úÖƵÄÑо¿Èç»ðÈçݱ £¬»¼Õß¹ÜÀíÓëÕÕ»¤Ò²Ã»Óб»ÎÒÃǺöÂÔ £¬¶à·½Ò»Í¬Å¬Á¦Íƽø¡°ÄÔ½¡¿µÐж¯¡± £¬²ÅÆøÈá°ÈËÈËÏíÓÐÄÔ½¡¿µ¡±µÄÄ¿±ê×îÖո濢£¡
²Î¿¼ÎÄÏ×
[1] Cummings J, Zhou Y, Lee G, et al. Alzheimer’s disease drug development pipeline: 2023. Alzheimers Dement (N Y). 2023 May 25;9(2):e12385.
[2]Tahami Monfared AA, Ye W, Sardesai A, et a;. A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial. Neurol Ther. 2023 Jun;12(3):863-881.
[3] Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis.
[4]Ou YN, Yang YX, Deng YT, et al. Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood. Mol Psychiatry. 2021 Oct;26(10):6065-6073.
[5]Vadukul DM, Vrancx C, Burguet P, et al. An evaluation of the self-assembly enhancing properties of cell-derived hexameric amyloid-¦Â. Sci Rep. 2021 Jun 2;11(1):11570.
[6]Hardy J, Mummery C. An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next? Brain. 2023 Apr 19;146(4):1240-1242.
[7]van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023 Jan 5;388(1):9-21.
[8]Paroni G, Bisceglia P, Seripa D. Understanding the Amyloid Hypothesis in Alzheimer’s Disease. J Alzheimers Dis. 2019;68(2):493-510.
[9]Cummings J, Zhou Y, Lee G, et al. Alzheimer’s disease drug development pipeline: 2023. Alzheimers Dement (N Y). 2023 May 25;9(2):e12385.
[10]Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2020 Aug 25;324(8):772-781.
[11]Sindi S, Solomon A, K?reholt I, et al. Telomere Length Change in a Multidomain Lifestyle Intervention to Prevent Cognitive Decline: A Randomized Clinical Trial. J Gerontol A Biol Sci Med Sci. 2021 Feb 25;76(3):491-498.
